RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $125 from $120 and keeps an Outperform rating on the shares. Boston Scientific reported “impressive” Q2 results and raised its 2025 revenue growth and operating margin guidance, the analyst tells investors in a research note. RBC sees Boston Scientific as among the highest performing MedTech large-caps.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $118 from $110 at Oppenheimer
- Boston Scientific price target raised to $125 from $120 at Truist
- Boston Scientific price target raised to $123 from $117 at Baird
- Boston Scientific price target raised to $135 from $130 at UBS
- Boston Scientific price target raised to $124 from $118 at Wells Fargo